Kanghan Liu1, Yiya Yang1, Yinyin Chen1, Shiyao Li1, Yuting Gong1, Yumei Liang2. 1. Department of Nephrology and Laboratory of Kidney Disease, Hunan Provincial People's Hospital, Hunan Normal University, Hunan Clinical Research Center for Chronic Kidney Disease, No. 61 Jiefang West Road, Changsha, 410002, Hunan, P. R. China. 2. Department of Nephrology and Laboratory of Kidney Disease, Hunan Provincial People's Hospital, Hunan Normal University, Hunan Clinical Research Center for Chronic Kidney Disease, No. 61 Jiefang West Road, Changsha, 410002, Hunan, P. R. China. liangyumei0115@163.com.
Abstract
OBJECTIVE: IgA nephropathy (IgAN) is one of the most common glomerulonephritis in the world, especially in Asian population. IgAN usually progresses slowly, but it is still an important cause of chronic renal failure. IgAN is characterized by abnormal increase of IgA1 level and deposition in mesangium. At present, there is no specific treatment. MATERIALS AND METHODS: Previous reports have shown that DC cells expressing immunosuppressive factors can significantly reduce the symptoms of arthritis in arthritis models. Indoleamine 2,3-dioxygenase (IDO) is an important tryptophan degrading enzyme and an important factor regulating immunotolerance. DC expressing functional IDO can inhibit effector T cells by consuming essential tryptophan and/or producing toxic metabolites and promoting the differentiation of Treg cells, which exhibits immunosuppressive effect. In this study, we constructed a IgAN mouse model. The mature DC cells overexpressing IDO were induced in vitro and transfused back to IgAN mice to observe their effects on inflammation and renal injury. RESULTS: The results showed that overexpression of IDO did not affect the maturation of DC cells. The proportion of CD3 + CD4 + and CD3 + CD8 + cells decreased significantly and the proportion of CD4 + CD25 + Foxp3 + cells increased significantly in kidney tissue of IgAN mice after the reinfusion of IDO-expressing DC. The contents of IL-2, IL-4, IL-6, and IL-17A in kidney tissue of IgAN mice also decreased significantly, the damage of kidney tissue was alleviated, ACR was decreased, collagen fibre content in kidney tissue was decreased, and IgA deposition in glomerular mesangium was decreased in IgAN mice. CONCLUSIONS: It has the potential to treat IgAN by upregulating the expression of IDO in DC cells by genetic engineering and reinfusion into vivo.
OBJECTIVE:IgAnephropathy (IgAN) is one of the most common glomerulonephritis in the world, especially in Asian population. IgAN usually progresses slowly, but it is still an important cause of chronic renal failure. IgAN is characterized by abnormal increase of IgA1 level and deposition in mesangium. At present, there is no specific treatment. MATERIALS AND METHODS: Previous reports have shown that DC cells expressing immunosuppressive factors can significantly reduce the symptoms of arthritis in arthritis models. Indoleamine 2,3-dioxygenase (IDO) is an important tryptophan degrading enzyme and an important factor regulating immunotolerance. DC expressing functional IDO can inhibit effector T cells by consuming essential tryptophan and/or producing toxic metabolites and promoting the differentiation of Treg cells, which exhibits immunosuppressive effect. In this study, we constructed a IgAN mouse model. The mature DC cells overexpressing IDO were induced in vitro and transfused back to IgAN mice to observe their effects on inflammation and renal injury. RESULTS: The results showed that overexpression of IDO did not affect the maturation of DC cells. The proportion of CD3 + CD4 + and CD3 + CD8 + cells decreased significantly and the proportion of CD4 + CD25 + Foxp3 + cells increased significantly in kidney tissue of IgAN mice after the reinfusion of IDO-expressing DC. The contents of IL-2, IL-4, IL-6, and IL-17A in kidney tissue of IgAN mice also decreased significantly, the damage of kidney tissue was alleviated, ACR was decreased, collagen fibre content in kidney tissue was decreased, and IgA deposition in glomerular mesangium was decreased in IgAN mice. CONCLUSIONS: It has the potential to treat IgAN by upregulating the expression of IDO in DC cells by genetic engineering and reinfusion into vivo.
Entities:
Keywords:
Cytokine; DC; IDO; IgA nephropathy; Treg
Authors: Seon Hee Kim; Nicole Bianco; Rajasree Menon; Eric R Lechman; William J Shufesky; Adrian E Morelli; Paul D Robbins Journal: Mol Ther Date: 2005-11-07 Impact factor: 11.454
Authors: Seon-Hee Kim; Eric R Lechman; Nicole Bianco; Rajasree Menon; Annahita Keravala; Joan Nash; Zhibao Mi; Simon C Watkins; Andrea Gambotto; Paul D Robbins Journal: J Immunol Date: 2005-05-15 Impact factor: 5.422
Authors: Andrew L Mellor; Babak Baban; Phillip R Chandler; Anna Manlapat; David J Kahler; David H Munn Journal: J Immunol Date: 2005-11-01 Impact factor: 5.422
Authors: Jan-Willem Eijgenraam; Susanne M Reinartz; Sylvia W A Kamerling; Vanessa J van Ham; Kim Zuidwijk; Cornelis M van Drunen; Mohamed R Daha; Wytske J Fokkens; Cees van Kooten Journal: Nephrol Dial Transplant Date: 2007-11-22 Impact factor: 5.992
Authors: Madhav D Sharma; De-Yan Hou; Yanjun Liu; Pandelakis A Koni; Richard Metz; Phillip Chandler; Andrew L Mellor; Yukai He; David H Munn Journal: Blood Date: 2009-04-14 Impact factor: 22.113